MiNK Therapeutics, Inc. (INKT) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
MiNK Therapeutics, Inc. (INKT) Earnings Overview
As of June 28, 2026, MiNK Therapeutics, Inc. (INKT) reported trailing twelve-month net income of -$12M, reflecting -4.6% year-over-year growth. The company earned $-2.60 per diluted share over the past four quarters.
Looking at the long-term picture, INKT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$11M in fiscal 2024.
MiNK Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$130M net income, -2051.1% margin), CELC (-$193M net income), TCRX (-$124M net income, -1256.8% margin), INKT has comparable earnings metrics. Compare INKT vs FATE →
INKT Earnings vs Peers
Earnings metrics vs comparable public companies
INKT Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$12M | -15.9% | -$12M | $-2.93 | - | - |
| 2024 | -$11M | +52.0% | -$11M | $-2.80 | - | - |
| 2023 | -$22M | +19.8% | -$23M | $-6.54 | - | - |
| 2022 | -$28M | +7.4% | -$31M | $-8.31 | - | - |
| 2021 | -$30M | -86.1% | -$19M | $-9.03 | - | - |
| 2020 | -$16M | +31.8% | -$11M | $-4.91 | - | - |
| 2019 | -$24M | - | -$22M | $-10.80 | -3451.5% | -3231.4% |
Download Data
Export INKT earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
INKT — Frequently Asked Questions
Quick answers to the most common questions about buying INKT stock.
What is INKT earnings per share (EPS)?
INKT trailing twelve-month (TTM) diluted EPS is $-2.60, reflecting -4.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is MiNK Therapeutics, Inc.'s net income?
MiNK Therapeutics, Inc. (INKT) trailing twelve-month net income is $-12M as of 2025. Earnings declined -4.6% year-over-year.
Is INKT profitable?
INKT is not currently profitable on a TTM basis, reporting a net loss of $-12M. Net margin is N/A. Investors should monitor for a return to profitability.
What is INKT's earnings growth rate?
INKT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are INKT's profit margins?
MiNK Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is INKT growing earnings?
INKT earnings growth is slowing. Current YoY EPS growth of -4.6% trails the 5-year CAGR of N/A. TTM net income is $-12M.
What was INKT's best earnings year?
MiNK Therapeutics, Inc.'s highest annual net income on record is $-11M, achieved in fiscal year 2024. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were INKT's earnings last quarter?
INKT's most recent reported quarter was Q1 2026. Net income was $-3M with diluted EPS of $-0.57. For a full breakdown of all quarters, see the quarterly earnings table on this page.